Therapeutic Insights
Filter News
Found 459 articles
-
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”
-
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
-
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
In what is sure to create widespread skepticism — or enthusiasm, a study published in Nature Aging found that use of erectile dysfunction medication Viagra was associated with a 69% lower incidence of Alzheimer’s disease.
-
Halberd Follow-Up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE
12/6/2021
Halberd Corporation (OTC PINK: HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF).
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Researchers are working to develop new treatments for Alzheimer's disease and dementia and improve the already existing ones. Find out more here.
-
Researchers studied the behavior of protein cells in the brain and found a significant difference in those who have had dementia and those who have not, particularly in their ability to clean themselves.
-
Richard S. Isaacson, M.D., Joins Florida Atlantic University To Lead Alzheimer's Disease Prevention
11/30/2021
Florida Atlantic University is pleased to welcome Richard S. Isaacson, M.D., a world-renowned neurologist and researcher, as director of the newly launched FAU Center for Brain Health within the Schmidt College of Medicine, established through the generous support of The Harry T. Mangurian, Jr. Foundation.
-
Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022
11/30/2021
Organovo Holdings, Inc., provided a business overview and progress update, and announced it is on track to establish its first models of inflammatory bowel disease in 2022 using its 3D bioprinting and other 3D tissue technologies.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
Even before the drug's approval on June 7, there were cases of amyloid-related imaging abnormalities (ARIA-E), or cerebral edema, observed in the trials.
-
Halberd Successfully Eradicates TNF-a, a Major Contributing Factor to Alzheimer’s Disease
11/22/2021
Halberd Corporation successfully eradicated 85% of Tumor Necrosis Factor-alpha from synthetic cerebral spinal fluid in preliminary testing.
-
Halberd Successfully Eradicates TNF-alpha, Major Contributing Factor to Alzheimer's Disease
11/22/2021
Halberd Corporation (OTC Pink: HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing.
-
In a Bloomberg News survey of 25 large insurers, none described the drug as “medically necessary,” and said Aduhelm was still experimental.
-
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
11/19/2021
Vertex Pharmaceuticals Incorporated announced that the Spanish government has approved terms for the national reimbursement of KAFTRIO® in a combination regimen with ivacaftor for the treatment of cystic fibrosis for eligible patients.